# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Novo Nordisk's FLOW trial reveals a 24% reduction in kidney disease progression, cardiovascular events, and death with sema...
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.
Fresenius Medical Care Q4 2023 revenue: €4.9 billion. Patient volume growth is expected at 0.5%-2% in 2024.
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue...